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ofBACKGROUND Stress cardiac magnetic resonance imaging (CMR) has demonstrated excellent diagnostic and
prognostic value in single-center studies.
OBJECTIVES This study sought to investigate the prognostic value of stress CMR and downstream costs from
subsequent cardiac testing in a retrospective multicenter study in the United States.
METHODS In this retrospective study, consecutive patients from 13 centers across 11 states who presented with a chest
pain syndrome and were referred for stress CMR were followed for a target period of 4 years. The authors associated CMR
findings with a primary outcome of cardiovascular death or nonfatal myocardial infarction using competing risk-adjusted
regression models and downstream costs of ischemia testing using published Medicare national payment rates.
RESULTS In this study, 2,349 patients (63  11 years of age, 47% female) were followed for a median of 5.4 years.
Patients with no ischemia or late gadolinium enhancement (LGE) by CMR, observed in 1,583 patients (67%), experienced
low annualized rates of primary outcome (<1%) and coronary revascularization (1% to 3%), across all years of study
follow-up. In contrast, patients with ischemiaþ/LGEþ experienced a >4-fold higher annual primary outcome rate and a
>10-fold higher rate of coronary revascularization during the first year after CMR. Patients with ischemia and LGE both
negative had low average annual cost spent on ischemia testing across all years of follow-up, and this pattern was similar
across the 4 practice environments of the participating centers.
CONCLUSIONS In a multicenter U.S. cohort with stable chest pain syndromes, stress CMR performed at experienced
centers offers effective cardiac prognostication. Patients without CMR ischemia or LGE experienced a low incidence
of cardiac events, little need for coronary revascularization, and low spending on subsequent ischemia testing.
(Stress CMR Perfusion Imaging in the United States [SPINS]: A Society for Cardiovascular Resonance Registry Study;
NCT03192891) (J Am Coll Cardiol 2019;74:1741–55) © 2019 The Authors. Published by Elsevier on behalf of the American
College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
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CAD = coronary artery disease
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resonance imaging
LGE = late gadolinium
enhancement
MI = myocardial infarction
PCI = percutaneous coronary
intervention
XCA = x-ray coronary
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1742R andomized multicenter studies (1–3)have demonstrated the high accu-racy of vasodilator stress cardiac
magnetic resonance imaging (CMR) in
detecting coronary stenoses and in esti-
mating impaired flow reserve (4) in coronary
artery disease (CAD). Stress CMR has also
been shown in many studies to be an effec-
tive cardiac prognosticating method for pa-
tients presenting with chest pain
syndromes (5–8). The American College of
Cardiology Foundation and American Heart
Association have recommended stress CMR
as an appropriate test for evaluation of
symptomatic patients with intermediate tohigh pre-test probability for CAD (9). However, stress
CMR remains an underutilized method in the United
States. Here we present the results of the SPINS
(Stress CMR Perfusion Imaging in the United States:
A Society for Cardiovascular Resonance Registry
Study) SCMR (Study of the Society for Cardiovascular
Magnetic Resonance) registry. SPINS is a multicenter
observational study of patients with stable chest
pain syndromes designed to evaluate the long-term
performance of stress CMR for cardiovascular
prognosis and to investigate the cost of additional
downstream cardiac testing following the index stress
CMR.SEE PAGE 1756METHODS
REGISTRY DESIGN AND PATIENT POPULATION.
Goals and infrastructures of the SCMR registry have
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aimed to test the primary hypothesis that evidence of
ischemia or infarction characterized by CMR provides
effective cardiovascular risk stratification in patients
with chest pain syndromes who are at intermediate to
high pre-test likelihood of significant coronary dis-
ease. The study aimed to enroll consecutive patients
who underwent a clinical vasodilator stress CMR in
the United States. Inclusion criteria were: 1) age be-
tween 35 and 85 years at the time of CMR; 2) referral
for evaluation of chest pain, dyspnea, abnormal
electrocardiogram, or other clinical presentation that
raised a suspicion of myocardial ischemia as deter-
mined by the treating clinician; and 3) presence of at
least 2 of the following coronary risk factors: age >50
years for male or >60 years for female subjects; dia-
betes mellitus requiring medical treatment; chronic
hypertension requiring treatment; hypercholester-
olemia on medical treatment; family history of pre-
mature CAD defined as diagnosis in a first-degree
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years old; body mass index $30 kg/m2; medically
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of percutaneous coronary intervention (PCI) or
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1743SELECTION OF ENROLLING CENTERS AND CMR
METHODS. An enrolling center was required to:
1) have an active clinical vasodilator stress CMR
perfusion imaging program ongoing for at least 10
years; 2) contribute between 100 and 500 consecutive
patients who underwent a vasodilator stress CMR
perfusion study between January 1, 2008, and
December 31, 2013, so that at least 4 years of clinical
follow-up could be achieved at study conclusion; and
3) have access to electronic medical records. Each
center was also required to have all CMR scans
interpreted by a Core Cardiology Training Symposium
level II or III reader, with at least 1 Core Cardiology
Training Symposium level III supervising reader.
Enrolling centers must have performed CMR studies
using either a 1.5-T or a 3-T scanner and pulse se-
quences for stress perfusion, cine, and late gadolin-
ium enhancement (LGE) imaging of infarction.
Enrolling centers were also required to have reported
the myocardial extent of abnormal stress perfusion
and LGE according to the 16-segment or 17-segment
American Heart Association nomenclature. At each
participating site, local institutional review board
approval was obtained to conduct this clinical follow-
up study with a waiver of written informed consent.
SAMPLE SIZE CALCULATION. Sample size of the
study was calculated to accrue at least 150 cases of all-
cause death or acute MI for the purpose of deter-
mining the prognostic value of ischemia by stress
CMR with adjustment for up to 10 known clinical risk
variables. Based on a prior publication (8), prevalence
of ischemia on stress CMR for the study cohort was
estimated to be 23%. Incidence rates of all-cause
death or acute MI were estimated to be 0.5% and
6.0% per year in patients with absence and presence
of ischemia, respectively. Over a 4-year follow-up, at
least 124 of 506 patients with ischemia and 36 of 1,694
patients without ischemia, were expected to have
died or experienced an acute MI, thus an estimated
target sample size of approximately 2,200 patients
was needed to yield a power of 80% with an alpha
error of 5% to detect a difference of >20% for the
primary outcome between the patient groups with a
normal versus abnormal stress CMR.
DATA COLLECTION. Enrolling centers entered all
study-related protected health information–free data
into the CMR Cooperative encrypted web-based
database (CMRcoop) for GCMR (Global CMR Regis-
try). Clinical variables collected included patient de-
mographics, clinical history (prior heart disease and
coronary risk factors), and study indication. CMR
variables included left ventricular volumes and di-
mensions, and stress perfusion and LGE (both re-
ported as presence or absence on a segmental basis)using the American Heart Association segmental
models. A stress perfusion defect was considered
present if it was densest in the endocardium with a
transmural gradient across the wall thickness, per-
sisted beyond peak myocardial enhancement and for
several R-R intervals, and conformed to a coronary
arterial distribution. Inducible ischemia (ischemiaþ)
was defined as the presence of a stress perfusion
defect, in absence of matching LGE, in $1 segment
(11). MI was defined as the presence of LGE (LGEþ)
conforming to infarction in $1 segment. Mild, mod-
erate, and severe defects were defined as the
involvement of 1 to 2, 3 to 5, and $6 myocardial
segments, respectively. To determine the diagnostic
value of stress CMR, we collected the CMR in-
terpretations as reported by center readers at the
time of study performance. For quality assurance,
each center randomly selected 10% of its CMR studies
and submitted the images for blinded interpretation
by the CMR core lab at the Brigham and Women’s
Hospital to evaluate core lab versus center agree-
ment. Information regarding performance of all
subsequent noninvasive tests for CAD during the
follow-up period, including exercise stress testing,
stress echocardiography, nuclear perfusion imaging,
coronary computed tomographic angiography, repeat
stress CMR, and invasive x-ray coronary angiography
(XCA) was collected.
STUDY ENDPOINTS. All centers were instructed to
obtain clinical follow-up data on all enrolled patients
for at least 4 years after the index stress CMR. Clinical
follow-up used both electronic medical records and
direct patient contact with either a standardized
checklist questionnaire or scripted telephone inter-
view. Study investigators were trained during the
initiation period, by group webinars and study doc-
uments, on specific definitions of all key variables
required on the web-based database. All outcome
variables and their standardized published clinical
trial definitions were posted on the web database (12).
Follow-up data was verified by each site’s principal
investigator. In the final 6 months of the study
period, a data quality report was generated by the
data-coordinating center in Boston and sent weekly
to each site. Primary outcome was defined as cardio-
vascular death or nonfatal MI. Secondary outcome
was defined by a composite of cardiovascular death,
nonfatal MI, hospitalization for unstable angina or
congestive heart failure, and late unplanned CABG.
Deaths were categorized as cardiovascular, cancer, or
cause unknown. Cardiovascular deaths were deaths
preceded by an acute MI, malignant ventricular
arrhythmia, or decompensated heart failure. Acute MI
diagnosis required chest pain or anginal equivalent
TABLE 1 Demographics and Baseline Characteristics
Overall
(N ¼ 2,349)
No Ischemia or
LGE (n ¼ 1,583)
Ischemia or
LGE (n ¼ 766) p Value
Clinical data
Follow-up, yrs 5.4 (4.6–6.8) 5.5 (4.6–6.9) 5.3 (4.3–6.5) <0.001
Age, yrs 63  11 62  11 63  11 0.61
Female 1,104 (47.0) 821 (52.0) 283 (37.0) <0.001
BMI, kg/m2 31  7 31  7 30  7 <0.001
No. of cardiac risk factors 3 (2–4) 3 (2–4) 4 (3–5) <0.001
Risk factors*
Hypertension 1,843 (78.0) 1,196 (76.0) 647 (85.0) <0.001
Hypercholesterolemia 1,647 (70.0) 1,053 (67.0) 594 (78.0) <0.001
Diabetes mellitus 664 (28.0) 409 (26.0) 255 (33.0) <0.001
Significant smoking, >10 pack-yrs 757 (32.0) 457 (29.0) 300 (40.0) <0.001
History of premature CAD in first-degree relative 761 (34.0) 495 (32.0) 266 (37.0) 0.03
CAD Consortium score, basic† 34 (24–54) 34 (17–47) 44 (28–54) <0.001
History of PCI‡ 538 (23.0) 244 (15.0) 294 (38.0) <0.001
History of MI‡ 358 (15.0) 110 (7.0) 248 (33.0) <0.001
History of heart failure‡ 245 (10.0) 113 (7.0) 132 (17.0) <0.001
Presenting reasons
Chest pain 1,303 (55.0) 885 (56.0) 418 (55.0) 0.60
Dyspnea or fatigue on exertion 509 (22.0) 338 (21.0) 171 (22.0) 0.59
Abnormal ECG 159 (6.8) 99 (6.3) 60 (7.8) 0.16
Arrhythmias 154 (6.6) 122 (7.7) 32 (4.2) 0.001
Syncope 50 (2.0) 30 (1.9) 20 (2.6) 0.29
Peripheral edema 6 (0.3) 4 (0.3) 2 (0.3) 1.00
Abnormal stress nuclear imaging 16 (0.7) 12 (0.8) 4 (0.5) 0.60
Abnormal stress echocardiography 29 (1.2) 19 (1.2) 10 (1.3) 0.84
Abnormal exercise stress test 10 (0.4) 8 (0.5) 2 (0.3) 0.51
Other symptoms and/or reasons 113 (4.8) 67 (4.2) 46 (6.0) 0.06
Stress CMR
Scanner field strength
1.5-T 1,535 (65.0) 1,054 (67.0) 481 (63.0) 0.07
3.0-T 814 (35.0) 529 (33.0) 285 (37.0)
CMR manufacturers§
Siemens 1,615 (69.0) 996 (63.0) 619 (81.0) <0.001
General Electric 512 (22.0) 427 (27.0) 85 (11.0)
Phillips 221 (9.0) 159 (10.0) 62 (8.0)
LVEF, % 63 (54–70) 65 (58–72) 57 (46–66) <0.001
LVEDVI, ml/m2 64 (50–79) 60 (48–73) 71 (57–89) <0.001
LVESVI, ml/m2 22 (16–32) 20 (15–28) 28 (20–44) <0.001
Inducible ischemia 405 (17.0) 0 (0.0) 405 (53.0) <0.001
MI 571 (24.0) 0 (0.0) 572 (75.0) <0.001
Values are median (IQR), mean  SD, or n (%). *Full risk factor profile missing for 123 patients. †CAD Consortium score missing for 332 patients. ‡History of PCI, MI, and CHF
missing for 5, 17, and 4 patients, respectively. §Manufacturer information missing for 1 patient.
BMI ¼ body mass index; CAD ¼ coronary artery disease; CMR ¼ cardiac magnetic resonance imaging; ECG ¼ electrocardiogram; IQR ¼ interquartile range; LGE ¼ late
gadolinium enhancement; LVEF ¼ left ventricular ejection fraction; LVEDVI ¼ left ventricular end-diastolic volume index; LVESVI ¼ left ventricular end-systolic volume index;
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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1744and abnormal troponins with temporal changes
consistent with myocardial injury. The cutoff levels
of troponins were according to the specifications at
the individual centers. Hospitalization for unstable
angina was defined as an unscheduled hospitalization
due to worsening chest pain or anginal equivalent,
combined with evidence of ischemia by imaging or
significant coronary stenosis by computed tomogra-
phy or XCA. Heart failure hospitalization was defined
as an unscheduled hospitalization due to worseningor new symptoms and/or signs of heart failure, >24 h
of in-hospital stay, and intensification of heart failure
treatment. Late unplanned CABG was defined as
CABG performed >6 months after the index stress
CMR. CABG was included as an event because, in
general, it signifies the discovery of a life-threatening
high-risk CAD state (e.g., left-main or multivessel
disease) where CABG is used as a life-saving proced-
ure; this is in contrast to elective PCI procedures,
which are often performed to treat non–life-
FIGURE 1 Primary and Secondary Outcome Event Rates
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1745threatening CAD (e.g., relief of angina). For either
primary or secondary outcome, only the first event
was counted when multiple events occurred in a
subject. A successful follow-up was defined as
achieving an assessment of all outcome events for $4
years after the index CMR. End of follow-up data
collection and locking of database occurred on
May 25, 2018.
COSTS OF CARDIAC ISCHEMIA TESTING AFTER INDEX
STRESS CMR. All enrolling centers collected perfor-
mance of all ischemia testing including stress single-
photon emission computed tomography, coronary
computed tomographic angiography, stress echocar-
diography, exercise treadmill test, repeat stress CMR,
and XCA during the study follow-up period. As shown
in Online Table 1, the corresponding costs of these
procedures were determined based on published
average national payment rates from the Medicare
Hospital Outpatient Prospective Payment System,
specific to the technical component of the most
common Healthcare Common Procedure CodingSystem code and the year of the procedure. For pay-
ment rates of any procedures that were not published
in 2008 to 2010, the corresponding 2011 payment
rates were used. Procedure-specific costs and total
cardiac testing cost were calculated by adding up the
estimated Medicare payments for each procedure and
from all procedures, respectively, then expressing
them as costs per patient-years. Costs due to com-
plications of test procedures, including cancers
related to medical radiation, were not collected. Pa-
tients with <90 days of follow-up were excluded from
this analysis.
STATISTICAL ANALYSIS. Continuous variables were
compared by Student’s t-test or analysis of variance
and categorical variables by chi-square test as
appropriate. Annualized event rates were calculated
by dividing the number of patients who experienced
the event by patient-years of follow-up. We used a
Fine and Gray competing risk model to characterize
all cumulative incidence functions for the primary
and secondary outcomes, accounting for the effects of
FIGURE 2 Primary Outcome Over Years of Follow-Up
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Occurrence of primary outcome across different years of study follow-up, stratified by presence and/or absence of ischemia and left
gadolinium enhancement (LGE).
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1746competing risks from noncardiovascular deaths (13).
We first constructed multivariable clinical models, for
primary and secondary outcomes, respectively, by
including all clinical covariates with p < 0.1 on uni-
variable screening and <10% imputed or missing
data. Presence (þ) or absence () of ischemia and LGE
were then added separately to each clinical model to
determine whether they each provided incremental
and independent prognostic value adjusted to the
covariates in the models. Cumulative incidence
curves were generated by plotting cumulative inci-
dence of primary or secondary outcome by time of
follow-up. Proportional hazards assumption was then
evaluated using visual inspection of the log-log sur-
vival curves and the Schoenfeld residuals test. All
statistical analyses were performed using SAS
version 9.4 (SAS Institute, Cary, North Carolina) and
p < 0.05 was used to establish statistical significance.
RESULTS
BASELINE PATIENT DEMOGRAPHICS AND CMR
CHARACTERISTICS. A total of 2,370 patients from 13
participating centers and 11 states met inclusion and
exclusion criteria. Of these, 21 patients (0.9%)
had incomplete studies (missing or nondiagnosticperfusion or LGE images), and the remaining 2,349
patients formed the cohort. Patient demographics are
summarized in Table 1. Practice environments of the
participating centers included university hospitals
(n ¼ 7), cardiovascular group practices (n ¼ 2), mul-
tispecialty practices (n ¼ 2), and U.S. government or
military hospitals (n ¼ 2). Primary indication for stress
CMR included chest pain (55%), dyspnea (22%),
changes on resting electrocardiogram suspicious of
ischemia (7%), syncope or cardiac dysrhythmias (9%),
and others (7%). Symptoms of patients with changes
on resting electrocardiogram as the primary indica-
tion were not known. The mean age in the cohort was
63  11 years with 47% of the cohort was female.
There was a high prevalence of hypertension (78%)
and dyslipidemia (70%). Median number of cardiac
risk factors was 3 (interquartile range: 2 to 4). A his-
tory of MI and PCI were present in 15% and 23% of the
cohort, respectively. Median basic CAD Consortium
Score (14) was 34% (mean 38  20%), which is indic-
ative of an average intermediate pre-test likelihood of
CAD. A 3-T scanner was used in 35% and magnetic
resonance imaging vendors included all 3 top
manufacturers (Siemens Healthineers, Erlangen,
Germany: 69%; General Electric Healthcare, Prince-
ton, New Jersey: 22%; and Philips Medical Systems,
FIGURE 3 Need for Coronary Revascularization
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Occurrence of coronary revascularization across different years of study follow-up, stratified by presence and/or absence of ischemia and left
gadolinium enhancement (LGE).
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1747Amsterdam, the Netherlands: 9%). Gadolinium-
based contrast agents included gadopentetate–
diethylenetriamine pentaacetic acid (Magnevist,
Bayer AG, Leverkusen, Germany) in 1,457 (62%),
gadodiamide (Omniscan, GE Healthcare) in 400 (17%),
gadobenate (Multihance, Bracco Diagnostics, Milan,
Italy) in 246 (10.5%), gadoversetamide (Optimark,
Guerbet, Villepinte, France) in 150 (6.4%), gadoter-
idol (Prohance, Bracco Diagnostics) in 91 (3.9%), and
gadobutrol (Gadavist, Bayer AG) in 5 patients (0.2%).
Average left ventricular size and function were within
normal limits. Ischemia and LGE were present in 17%
and 24% of patients, respectively, and 14% (of 24%) of
the patients with LGE had no clinical history of MI.
Overall, 766 patients (33%) had an abnormal stress
CMR, defined as the presence of either ischemia or
LGE. Within the 766 patients, 194 (8%) had ischemia
but no LGE, 361 (15%) had LGE but no ischemia, and
211 (9%) had both ischemia and LGE. In this cohort, 40
patients (1.7%) were diagnosed to have non-CAD
cardiac conditions on CMR. These included 3 new
cases of cardiac amyloidosis, 5 cases of hypertrophic
cardiomyopathy, 5 cases of myocarditis, 5 cases of
nonischemic dilated cardiomyopathy, 8 cases ofpericardial disease, 1 case of cardiac sarcoidosis, and
13 cases of nonspecific myocardial fibrosis. Apart from
these conditions, 339 (14%) were found to have LGE
consistent with unrecognized MI.
CMR PROGNOSIS FOR PRIMARY AND SECONDARY
OUTCOME. Successful follow-up of $4 years was
achieved in 2,294 patients (97.7%) with a median
follow-up of 5.5 years (interquartile range: 4.6 to 6.8
years). During study follow-up, 255 patients (11%)
died with 74 (3.2%) due to cardiovascular causes and
181 (7.7%) noncardiovascular causes. Primary
outcome occurred in 153 patients including, as a first
event, 87 nonfatal MI and 66 cardiovascular deaths.
Sixty-two of the nonfatal MI and 45 of the cardio-
vascular deaths occurred within the first 4 years of
follow-up. Secondary outcome occurred in 374 pa-
tients including, as a first event, 77 nonfatal MI, 124
hospitalizations for unstable angina, 86 hospitaliza-
tions for heart failure, 44 cases of late unplanned
CABG, and 43 cardiovascular deaths. Primary outcome
rates, expressed as percentage per patient-year,
stratified by CMR findings of ischemia and LGE, are
shown in Figure 1. Among the 1,583 patients (67%)
who had no ischemia and no LGE (ischemia/LGE),
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Cumulative incidence functions for primary and secondary outcomes derived from a Fine and Gray competing risk model accounting for noncardiovascular death as a
competing risk event. The top panels were stratified by presence and/or absence of ischemia and late gadolinium enhancement, and the bottom panels were stratified
by the extent of ischemia.
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1748primary and secondary outcome occurred at low rates
of 0.6% and 1.7% per patient-year, respectively. In
contrast, those with ischemiaþ and LGEþ experi-
enced rates of 4.5% and 10.1% per patient-year,
respectively. Patients with no, mild, moderate, and
severe ischemia extent experienced primary outcome
rates at 0.9%, 2.9%, 2.9%, and 3.1%, respectively; and
secondary outcome rates at 2.3%, 6.8%, 9.7%, and
6.9%, respectively. During the first 4 years of follow-
up, presence of ischemia was associated with an oddsratio of 4.2 for acute MI (p < 0.0001) and 2.4 for
cardiovascular death (p ¼ 0.004). Figure 2 demon-
strates the primary outcome rates stratified by the
time period of follow-up, year 1 through year 5. Pa-
tients with ischemia/LGE experienced low primary
outcome rates from year 1 to year 4 (0.3% to 0.7%/
year) and at 1.4% in year 5. In contrast, those with
ischemiaþ/LGEþ experienced the highest primary
outcome rates across all 5 years (ranging from 2.4% to
8.5%). Online Figure 1 demonstrates the secondary
TABLE 2 Univariable Association of Clinical and Stress CMR Indices With Outcome Using
a Fine and Gray Competing Risk Model
Primary Outcome Secondary Outcome
HR (95% CI) p Value HR (95% CI) p Value
Demographics
Age, per yr 1.01 (1.00–1.03) 0.06 1.01 (1.00–1.02) 0.10
Female 0.58 (0.42–0.81) 0.002 0.79 (0.64–0.97) 0.02
BMI, per kg/m2 1.00 (0.98–1.02) 0.89 1.00 (0.99–1.02) 0.76
Cardiac risk factors
Hypertension 1.53 (0.98–2.39) 0.06 2.05 (1.50–2.79) <0.0001
Hypercholesterolemia 1.02 (0.72–1.45) 0.90 1.23 (0.97–1.54) 0.09
Diabetes mellitus 1.67 (1.21–2.31) 0.002 1.51 (1.23–1.87) <0.001
Smoking 1.82 (1.32–2.51) <0.001 1.56 (1.27–1.93) <0.0001
Family history of CAD 0.75 (0.52–1.08) 0.12 1.00 (0.80–1.25) 0.98
Number of cardiac risk factors 1.36 (1.19–1.56) <0.0001 1.40 (1.29–1.53) <0.0001
CAD Consortium score, basic 1.02 (1.01–1.03) <0.0001 1.01 (1.01–1.02) <0.0001
History of PCI 2.73 (1.98–3.76) <0.0001 2.48 (2.02–3.06) <0.0001
History of MI 4.26 (3.08–5.88) <0.0001 2.79 (2.23–3.48) <0.0001
History of CHF 3.71 (2.60–5.30) <0.0001 2.72 (2.12–3.48) <0.0001
Stress CMR
LVEF, per % D 0.97 (0.96–0.98) <0.0001 0.97 (0.96–0.98) <0.0001
LVEDVI, per ml/m2 D 1.01 (1.01–1.02) <0.0001 1.01 (1.01–1.02) <0.0001
LVESVI, per ml/m2 D 1.02 (1.01–1.02) <0.0001 1.01 (1.01–1.02) <0.0001
Ischemiaþ 3.41 (2.46–4.73) <0.0001 3.30 (2.67–4.08) <0.0001
Extent of ischemia,
per segment
1.10 (1.07–1.14) <0.0001 1.11 (1.08–1.14) <0.0001
LGEþ 4.10 (2.97–5.65) <0.0001 3.24 (2.64–3.97) <0.0001
Extent of LGE, per segment 1.11 (1.08–1.14) <0.0001 1.09 (1.07–1.11) <0.0001
Abnormal CMR, ischemia or MI 3.85 (2.77–5.36) <0.0001 3.59 (2.91–4.42) <0.0001
Primary outcome was defined as cardiovascular death or nonfatal MI. Secondary outcome was defined by a
composite of cardiovascular death, nonfatal MI, hospitalization for unstable angina or CHF, and late unplanned
coronary arterial bypass surgery.
þ ¼ present; D ¼ difference; CHF ¼ congestive heart failure; CI ¼ confidence interval; HR ¼ hazard ratio; other
abbreviations as in Table 1.
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1749outcome rates by status of ischemia and LGE in a
similar format. Patients with ischemia/LGE expe-
rienced the lowest secondary events rates. Figure 3
demonstrates the need for coronary revasculariza-
tion in the whole cohort, stratified by the time pe-
riods of follow-up. In patients with ischemia/LGE,
coronary revascularization was needed in 3% in year 1
and in 1% for each of the subsequent years. Most
coronary revascularization in patients with
ischemiaþ/LGEþ occurred in the first 90 days.
The Central Illustration demonstrates event-free
survival with 95% confidence intervals, based on cu-
mulative incidence function for primary and sec-
ondary outcome and stratified by ischemia and LGE.
Stratified by ischemia and LGE, patients in the
ischemiaþ/LGEþ group had the highest cumulative
incidence of primary and secondary outcomes over
time, whereas in contrast patients in the ischemia/
LGE group had the lowest incidence. Patients with
ischemiaþ/LGE had incidence of primary and sec-
ondary outcomes over time that were not statistically
different from patients with ischemia/LGEþ. There
was progressively higher incidence over time with
greater extent of ischemia, for either primary
outcome or secondary outcome, although there was
statistical overlap between the moderate and severe
categories toward primary outcome. Univariable an-
alyses associating patient and CMR characteristics
with primary and secondary outcome are presented
in Table 2. For primary outcome, age, smoking, his-
tory of hypertension, diabetes, history of MI, history
of PCI, history of congestive heart failure, and left
ventricular end-systolic volume index were the
strongest set of clinical covariates selected from
univariable screening in forming the clinical model
for the primary outcome (2 log L: 1,950). Table 3
demonstrates the multivariable clinical models of
primary and secondary outcome. Presence of
ischemia and presence of LGE independently
improved this clinical model for primary outcome
when they were separately added (2 log L: 1,933 and
1,939, for ischemia and LGE, respectively, both
p < 0.0001) or when both added (2 log L: 1,927) to
the model. Adjusted to the effects of the covariates in
the clinical model and to each other, presence of
ischemia and presence of LGE both maintained sig-
nificant association with primary outcome (adjusted
hazard ratio: 1.96; 95% confidence interval: 1.35 to
2.86; p ¼ 0.0004; and adjusted hazard ratio: 1.64; 95%
confidence interval: 1.08 to 2.51; p ¼ 0.02, respec-
tively). Similar significant association was observed
for presence of ischemia and LGE with secondary
outcome. Both ischemia presence and extent also
demonstrated strong association with all-cause deathor nonfatal MI (hazard ratios: 1.84 and 1.28, respec-
tively, both p < 0.0001). Visual inspection of the log-
log survival curves and calculation of the Schoenfeld
residuals showed that the proportionality assumption
was not violated.
UTILIZATION OF INVASIVE TESTING AND CORONARY
REVASCULARIZATION AFTER CMR. Referrals to inva-
sive XCA and performance of coronary revasculari-
zation at 90 days after CMR per discretion of the
primary caring team, stratified by ischemia and LGE
and ischemia extent, are shown in Figure 4. Only 4%
of patients with ischemia/LGE were referred to
undergo CA, which compared with 46% among pa-
tients with ischemiaþ/LGEþ, with the presence of
ischemia being a key factor for referral to CA. Proba-
bilities of coronary revascularization procedure
(either PCI or CABG), once referred to CA, ranged
from 24% in the ischemia/LGE group to 73% in the
ischemiaþ/LGEþ group. Increasing extent of ischemia
was associated with stepwise higher likelihood of
referral to CA and coronary revascularization.
FIGURE 4 Invasive
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TABLE 3 Multivariable Models for Primary and Secondary Outcomes Using a Fine and Gray Competing Risk Model
Primary Outcome Secondary Outcome
Parameter
Estimate p Value HR (95% CI)
Parameter
Estimate p Value HR (95% CI)
Age, per yr 0.02 0.08 1.02 (1.00–1.03) 0.01 0.12 1.01 (1.00–1.02)
History of
PCI 0.37 0.09 1.45 (0.95–2.22) 0.49 0.0004 1.63 (1.25–2.14)
MI 0.72 0.003 2.05 (1.28–3.28) 0.29 0.07 1.34 (0.98–1.82)
CHF 0.65 0.01 1.92 (1.17–3.15) 0.50 0.004 1.65 (1.17–2.32)
Diabetes 0.30 0.10 1.35 (0.94–1.94) 0.22 0.07 1.24 (0.99–1.57)
Hypertension 0.17 0.46 1.19 (0.75–1.89) 0.55 0.001 1.73 (1.24–2.42)
Tobacco use 0.48 0.006 1.62 (1.15–2.28) 0.31 0.006 1.37 (1.09–1.71)
LVESVI, ml/m2 0.01 0.09 1.01 (1.00–1.01) 0.01 0.02 1.01 (1.00–1.01)
LGEþ 0.50 0.02 1.64 (1.08–2.51) 0.48 0.0005 1.62 (1.23–2.12)
Ischemiaþ 0.67 0.0004 1.96 (1.35–2.86) 0.73 <0.0001 2.08 (1.62–2.67)
Primary outcome was defined as cardiovascular death or nonfatal MI. Secondary outcome was defined by a composite of cardiovascular death, nonfatal MI, hospitalization for
unstable angina or CHF, and late unplanned coronary arterial bypass surgery.
Abbreviations as in Tables 1 and 2.
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1750COSTS SPENT ON ISCHEMIA TESTING DURING
STUDY FOLLOW-UP. During follow-up, 142 stress
echocardiography, 808 stress single-photon emission
computed tomography, 199 coronary computed
tomographic angiography, 149 repeat stress CMR, 215XCA and Revascularization at 90 Days
24%
38%
46%
10%
33%
46%
73%
Ischemia+/
LGE–
Ischemia–/
LGE+
mia–/
E–
Ischemia+/
LGE+
60%
40%
70%
50%
30%
20%
10%
0%
80%
Referred to CA Within 90 Days Coronary Rev
oronary angiography (XCA) at 90-day post-stress cardiac magnetic resonanc
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were performed. Figure 5 illustrates the average cost
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FIGURE 5 Costs of Ischemia Testing
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Costs of downstream cardiac tests incurred during follow-up, stratified by stress cardiac magnetic resonance imaging (CMR) findings with breakdown by modality.
Costs are in U.S. dollars spent per patient. CTA ¼ computed tomography angiography; LGE ¼ late gadolinium enhancement.
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1751spending across all periods of follow-up. During the
first 90 days after CMR, patients with ischemiaþ/
LGEþ incurred approximately 10-fold higher costs
than did those with ischemia/LGE in the same time
period ($585 vs. $54, p < 0.0001) due to the referral to
XCA. Whereas XCA contributed the most to overall
costs during the first year in patients with ischemiaþ
and to a lesser degree those with ischemia/LGEþ,
stress single-photon emission computed tomography
contributed the most in later years across all groups.
PATTERNS ACROSS DIFFERENT PRACTICE SETTINGS.
Characteristics of the enrolling centers are shown in
Online Table 2. University hospitals (n ¼ 7), cardio-
vascular group practices (n ¼ 2), multispecialty prac-
tices (n ¼ 2), and U.S. government or military
hospitals (n ¼ 2) enrolled 1,019 patients (43%), 464
(20%), 610 (26%), and 256 (11%), respectively. Over 4
years after CMR, 188 patients (8%), 81 (3.5%), and 15
(0.6%) had PCI, CABG, and both, respectively.
Figure 6 illustrates the performance of invasive XCA
at 90 days, by practice types and CMR findings.
Across all practice types, patients with ischemia/
LGE were referred to undergo XCA at 90 days at low
rates (2.8% to 4.9%). Patients with ischemiaþ un-
derwent XCA at substantially higher rates across all
practice types, the highest at 62% by the government/
military hospital group. As illustrated in Online
Figure 2, costs spent at 1 year demonstrated asimilar pattern across the practice types and
CMR findings.
CONCORDANCE RATES BETWEEN ENROLLING
CENTERS AND THE IMAGING CORE LABORATORY.
Images from 235 studies (10%) were interpreted by
the CMR core lab blinded to clinical characteristics
and outcomes. The concordance rates of centers
versus core lab interpretation on ischemia presence,
ischemia grade, LGE presence, and LGE grade were
82%, 86%, 90%, and 92%, respectively.
DISCUSSION
SPINS is the largest multicenter study in the United
States to date evaluating the prognostic value of stress
CMR in patients presenting with stable chest pain
syndromes. The study comprised a consecutive cohort
from centers with diverse practice settings with a
follow-up target of 4 years achieved in >97% of pa-
tients. There are 3 key findings (Central Illustration).
First, in this cohort with an intermediate pre-test
likelihood of CAD and a median basic consortium
score of 34%, 67% of the study cohort had ischemia/
LGE and experienced low annual rate of primary
and secondary outcomes after CMR (0.6% and
1.7%, respectively), which is in contrast to the
patients with ischemiaþ/LGEþ (4.5% and 10.1%,
respectively). Second, the need for referral to
FIGURE 6 Invasive XCA at 90 Days, Stratified by Practice Types
X-Ray Coronary Angiography at 90 Days,
by Practice Types and CMR Results
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Referral to invasive XCA at 90-day post stress CMR, stratified by presence and/or absence of ischemia and LGE, according to practice
environment. Abbreviations as in Figures 1, 4, and 5.
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1752coronary revascularization was low for patients with
ischemia/LGE, at 3% in the first year and <1% in
each of the subsequent 3 years, compared with 38%
and 3% for patients with ischemiaþ/LGEþ. Third, pa-
tients with ischemia/LGE had low average annual
costs spent on downstream ischemia testing across all
years of follow-up, and this finding is consistent across
practice types of the participating sites in the United
States.
As a gate-keeping noninvasive test, it is important
that a “low-risk” population be identified thereby
avoiding unnecessary downstream tests and invasive
treatment. From a cohort of 3,647 patients, the
multinational EuroCMR (European Cardiovascular
Magnetic Resonance) registry reported a negative
cardiovascular event rate as low as 1% per year,
demonstrating that stress CMR was effective in
obviating the need for invasive angiography (15,16).
The Italian STRATEGY (Stress Cardiac Magnetic
Resonance Versus Computed Tomography Coronary
Angiography for the Management of Symptomatic
Revascularized Patients) study observed that stressCMR has higher cost-effectiveness than coronary
computed tomography angiography in assessing
symptomatic patients with a history of coronary
revascularization (17). SPINS extended current
knowledge by examining the roles of stress CMR in
the U.S. health care system. Apart from low incidence
of primary and secondary outcomes, patients without
ischemia or LGE by CMR had low downstream need
for coronary revascularization and incurred low costs
for CAD testing throughout study follow-up. Stress
CMR is currently underutilized for chest pain assess-
ment compared with other noninvasive methods in
the United States; however, the performance charac-
teristics observed in SPINS strongly support the use of
stress CMR as an effective gatekeeping strategy for
invasive angiography.
It is increasingly recognized that the presence of
scar independently predicts adverse outcomes in CAD
(18). Studies have shown that CMR has excellent
sensitivity in detecting subendocardial infarctions
(19). In SPINS, the presence of either inducible
ischemia or LGE was independently associated with
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1753higher primary and secondary events. In addition, the
effects of inducible ischemia and LGE were additive,
such that patients with both findings were at the
highest risk. CMR also allows for the detection of un-
recognized MI, which is of prognostic importance. In a
large study of older community dwellers in Iceland,
the rate of unrecognizedMI by CMRwas 17% (20). Over
long-term follow-up, unrecognized MI by CMR was
associated with increased all-cause mortality. In our
study, although the prevalence of MI by LGE was 24%,
themajority (14%) did not have any prior history of MI,
highlighting the diagnostic importance of CMR.
In the current era of intense debate between
anatomical and functional testing in stable CAD, 2
large randomized trials have compared coronary
computed tomographic angiography to stress testing
(21,22). The PROMISE (Prospective Multicenter Im-
aging Study for Evaluation of Chest Pain) and SCOT-
HEART (Scottish Computed Tomography of the
Heart Trial) studies, however, included relatively
low-risk patients and did not include stress CMR as
part of their diagnostic strategies. Given its consistent
negative predictive value demonstrated in SPINS and
EuroCMR (16) and its lack of ionizing radiation
exposure, CMR is a practical choice when considering
stress testing. The MR-IMPACT (Magnetic Resonance
Imaging for Myocardial Perfusion Assessment in
Coronary Artery Disease Trial) I and II studies are
currently the largest prospective multicenter trials
that have included stress CMR (1,3). These studies
and CE-MARC (Clinical Evaluation of Magnetic Reso-
nance Imaging in Coronary Heart Disease) focused on
the diagnostic accuracy of CMR (23), whereas CE-
MARC 2 examined CMR’s impact on downstream
angiography use (24). The recently presented MR-
INFORM (MR Perfusion Imaging to Guide Manage-
ment of Patients With Stable Coronary Artery Disease)
study compared stress CMR with anatomic assess-
ment using XCA with fractional flow reserve in 918
symptomatic patients at high pre-test probability of
CAD (25). In this 1:1 randomized control trial, the
major adverse cardiac event rate was similar in both
strategies at 1-year follow-up.
Health care payers and patients are increasingly
aware of the cost burden from repeat cardiac testing in
noninvasive cardiovascular imaging. With the current
focus on value-based care, few studies have thus far
examined the downstream clinical and economic
values of stress CMR. In the current SPINS cohort,
downstream rate of coronary revascularization by
either PCI or CABG was the highest among patients
with ischemiaþ/ LGEþ. On the other hand, those with
ischemia/LGE by CMR had very low spending ratesfor ischemia testing or coronary revascularization. Our
results are congruent with the cost-minimization re-
sults of the EuroCMR registry (16).
STUDY LIMITATIONS. First, given the retrospective
design of this study, we could not capture all the
direct therapeutic and management decisions made
at the time of the CMR study. Second, CMR studies
were performed in a clinical setting so we cannot
determine whether any knowledge of coronary anat-
omy from prior angiography could have influenced
the CMR interpretations. Third, our participating sites
were predominantly tertiary-care experienced cen-
ters, therefore, there may have been a local referral
bias of higher-risk patients to CMR, and uncertainty
exists whether the current results generalize to less
experienced centers. Fourth, the SPINS study was
conducted at a time when quantitation of CMR
perfusion, LGE size, and invasive fractional flow
reserve were not performed as a clinical routine, thus,
these factors, which are relevant to today’s practice,
therefore could not be accounted for. Fifth, core lab
assessment of 10% of the images for ischemia and
LGE presence resulted in only a modest concordance
rate. Given the retrospective study design aimed at
capturing the clinical consequences of local inter-
pretation at time of CMR performance, there was no
attempt to standardize reading or interpretation
procedures between the enrolling centers and the
core lab. Finally, our study is not able to assess CMR
guidance of coronary revascularization toward
improving patient outcome, given its nonrandomized
study design and limited study power. This non-
randomized study design without a comparative
imaging-based strategy also prohibited any conclu-
sions in causal estimates or comparison against key
alternative methods in this setting. These limitations
will need to be addressed in prospective random-
ized trials.
CONCLUSIONS
Among patients with stable intermediate-risk chest
pain syndromes, a stress CMR without evidence of
ischemia or LGE was associated with very low inci-
dence of adverse cardiac events and low health care
costs spent on downstream cardiac testing.
ADDRESS FOR CORRESPONDENCE: Dr. Raymond Y.
Kwong, Brigham and Women’s Hospital, Cardiovas-
cular Division, Department of Medicine, Harvard
Medical School, 75 Francis Street, Boston, Massa-
chusetts 02115. E-mail: rykwong@bwh.harvard.org.
Twitter: @BrighamWomens.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: CMR
stress perfusion imaging can identify patients with chest
pain who are at risk of ischemic events and guide referral
for coronary revascularization. Implementation of stress
CMR as an initial diagnostic modality may prove less
costly than conventional strategies.
TRANSLATIONAL OUTLOOK: Future studies should
compare the cost and value of stress CMR with other
noninvasive modalities in the evaluation of patients with
suspected ischemic heart disease.
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